Oxford begins human trials for ebola vaccine
This vaccine is also unique in being multivalent - targeting multiple variants of the virus. By being able to target both Zaire and Sudan variants, the vaccine can be used in virtually all outbreaks and therefore governments can stockpile it, secure that it will be useful if a new outbreak appears.
Significant reductions in COVID-19 infections found after single dose of Oxford-AstraZeneca and Pfizer-BioNTech vaccine
"Researchers analysed nose and throat swabs and found that 21 days after a single dose of either Oxford-AstraZeneca or Pfizer-BioNTech vaccines (with no second dose), the rates of all new COVID-19 infections had dropped by 65%, symptomatic infections by 72% and infections without reported symptoms by 57%."
